CCND1 and prostate cancer: This analysis identified previously reported trans-enhancer hijacking events activating oncogenes CCND1 in the B-cell lymphoma cell line REC110,12 and ETV1 in the prostate cancer cell lines LNCaP and MDAPCA2B20,41,42.